The 2nd Annual Pacific Northwest Cardiovascular Summit 2016

Registration
Register online at www.pnwcvsummit.com

Registration fees
$285 – Register by September 1, 2016
$315 – Register by October 12, 2016

Cancellation and refunds
The conference registration fee is refundable minus a $25 processing fee if cancellation notice is received by September 23, 2016. After that date, the registration fee is 50% refundable until October 7, 2016. No refunds will be issued after that date.

Continuing education information

Course objective
At the end of the course, learners will be familiar with new insights and treatments appropriate for patients with lipid disorders, stable ischemic heart disease and hypertrophic cardiomyopathy.

Accreditation
Oregon Health & Science University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit
OHSU School of Medicine, Division of CME, designates this live activity for a maximum of 11 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Who should attend
This course is intended for cardiologists, primary care providers, advanced practice providers (physician assistants and nurse practitioners), and other health care professionals involved in the diagnosis, treatment and prevention of cardiovascular disease.

OHSU Knight Cardiovascular Institute Planning Committee
Michael D. Shapiro, D.O., Program Director
Stephen Skitmer, M.D.
James Mehl, M.D.
Sergio Faino, M.D., Ph.D.
Joanqut Ugarro, M.D.

Invited faculty

Euan Ashley, B.Sc., M.B., Ch.B., D.Phil.
Associate Professor of Cardiovascular Medicine & Genetics
Director, Center for Inherited Cardiovascular Disease
Chair, Biomethylation Data Science Initiative
Stanford University School of Medicine

Robert Bonow, M.D., M.S.
Goldberg Distinguished Professor of Cardiology
Northwestern University Feinberg School of Medicine

Henry Ginsberg, M.D.
Irving Professor of Medicine
Director, Irving Institute for Clinical & Translational Research
New York-Presbyterian/Columbia University Medical Center

David Maron, M.D.
Sarnoff Professor of Medicine (Cardiovascular)
Director, Preventive Cardiology
Tufts University School of Medicine

Martin Maron, M.D.
Associate Professor of Medicine
Director, Hypertrophic Cardiomyopathy Center
Tufts University School of Medicine

Steve Ommen, M.D.
Professor of Medicine
Medical Director, Hypertrophic Cardiomyopathy Clinic
Mayo Clinic

Frank Sacks, M.D.
Professor of Cardiovascular Disease Prevention
Professor of Genetics & Complex Diseases
Harvard T.H. Chan School of Public Health

Lisa Salberg
Founder and CEO, Hypertrophic Cardiomyopathy Association

Sotirios (Sam) Tsimikas, M.D.
Professor of Medicine
Director of Vascular Medicine
University of California, San Diego School of Medicine

James Udelson, M.D.
Professor of Medicine
Chief, Division of Cardiology
Tufts University School of Medicine

For complete bios and information, visit www.pnwcvsummit.com.

OHSU accepts most health plans.
OHSU is an equal opportunity, affirmative action institution.

NONPROFIT ORG
U.S. POSTAGE
PAID
Portland, OR
Permit No. 722
The 2nd Annual Pacific Northwest Cardiovascular Summit
October 15–16, 2016
Oregon Health & Science University (OHSU) Knight Cardiovascular Institute
is pleased to present the 2nd annual Pacific Northwest Cardiovascular Summit in Portland, Oregon. This weekend-long symposium provides the most up-to-date information about diagnosing and treating cardiovascular disease. Hear from internationally renowned experts speaking on topics related to preventive cardiology, stable ischemic heart disease and hypertrophic cardiomyopathy.

SATURDAY MORNING
October 15 / Preventive Cardiology
moderator: Sergio Fazio, M.D., Ph.D.
7:30 a.m. Registration and breakfast
8 a.m. Welcome
Michael B.升级, D.O.
9:30 a.m. Interaction of Diabetes and Atherosclerotic Cardiovascular Disease (ASCVD) Prevention
Henry Grodberg, M.D.
10 a.m. The Apolipoprotein C-III Story: From Metabolism to Risk Prediction to Treatment
Paul Sacks, M.D.
10:10 a.m. Break
11 a.m. The Enigmatic Particle – Evaluation and Management of Lp(a)
Sotirios (Sam) Tsimikas, M.D.
11:30 a.m. Cases and faculty panel discussion
Noon. Lunch

SATURDAY AFTERNOON
October 15 / Stable Ischemic Heart Disease
moderator: Joaquin Cigarroa, M.D.
2 p.m. Indications for Revascularization in Patients With CAD and LV Dysfunction
Robert Bonow, M.D., M.S.
4:10 p.m. Imaging in Stable Ischemic Heart Disease
James Udoff, M.D.
5:20 p.m. To Stent or Not to Stent – What Do the Clinical Trials Tell Us?
James Udoff, M.D.
6 p.m. Debate: Is There Still a Role for Viability Imaging?
PROTAGONIST: James Udoff, M.D.
ANTAGONIST: Robert Bonow, M.D., M.S.
7 p.m. Adjourn

SUNDAY MORNING
October 16 / Hypertrophic Cardiomyopathy
moderator: Stephen Heitner, M.D.
9:30 a.m. Multimodality Imaging in Hypertrophic Cardiomyopathy
Martin Maron, M.D.
10:10 a.m. Legislative Considerations in Pre-Participation Screening for Competitive Athletics
Lisa Salberg
11:30 a.m. Adjourn

Please visit www.pnwcvsummit.com for more information and to register.